<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04515849</url>
  </required_header>
  <id_info>
    <org_study_id>D5676C00001</org_study_id>
    <secondary_id>2020-000255-12</secondary_id>
    <nct_id>NCT04515849</nct_id>
  </id_info>
  <brief_title>A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Phase 2b, Multicentre, Randomised, Double-blind, Placebo-controlled, and Open-label Comparator Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 2b, study to measure the effect of Cotadutide at different doses versus placebo or&#xD;
      comparator (semaglutide) in participants who have Chronic Kidney Disease with Type 2 Diabetes&#xD;
      Mellitus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 2b randomised, double-blind, placebo-controlled and open-label active comparator&#xD;
      study to evaluate the effect of Cotadutide at 100, 300 or 600 micrograms in participants who&#xD;
      have Chronic Kidney Disease with Type 2 Diabetes Mellitus.&#xD;
&#xD;
      The study plans to randomise approximately 225 subjects. Subjects will be randomised to&#xD;
      receive double-blind Cotadutide or placebo at 100, 300 or 600 micrograms once daily for 26&#xD;
      weeks, or open-label semaglutide at 1.0 miligrams once a week for 26 weeks. Japanese&#xD;
      participants will not be randomised to the semaglutide arm.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 31, 2020</start_date>
  <completion_date type="Anticipated">March 7, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 7, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the effects of cotadutide at different dose levels compared to placebo on UACR after 14 weeks</measure>
    <time_frame>14 weeks</time_frame>
    <description>Change and percentage change in UACR versus placebo from baseline to the end of 14 weeks of dosing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the effects of cotadutide at different dose levels compared to placebo on UACR after 14 weeks</measure>
    <time_frame>14 weeks</time_frame>
    <description>Change and percentage change in UACR versus placebo from baseline to the end of 14 weeks of dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the effects of cotadutide at different dose levels compared to placebo on UACR after 26 weeks</measure>
    <time_frame>26 weeks</time_frame>
    <description>Change and percentage change in UACR versus placebo from baseline to the end of 26 weeks of dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the effects of cotadutide at different dose levels compared to placebo on HbA1c and fasting glucose</measure>
    <time_frame>26 weeks</time_frame>
    <description>Change in HbA1c versus placebo from baseline to the end of 14 and 26 weeks of dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the effects of cotadutide at different dose levels compared to placebo on HbA1c and fasting glucose</measure>
    <time_frame>26 weeks</time_frame>
    <description>Change in fasting glucose from baseline versus placebo after 14 and 26 weeks of dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the effects of cotadutide at different dose levels compared to placebo on glucose levels as measured by CGM</measure>
    <time_frame>26 weeks</time_frame>
    <description>Change in 10-day average glucose levels as measured by CGM versus placebo from baseline to the end of 14 and 26 weeks of dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the effects of cotadutide at different dose levels compared to placebo on glucose levels as measured by CGM</measure>
    <time_frame>26 weeks</time_frame>
    <description>Change in percentage time spent in hyperglycaemia (&gt; 10 mmol/L), target range (3.9 -10 mmol/L), hypoglycaemia (&lt; 3.9 mmol/L), and clinically significant hypoglycaemia (&lt; 3.0 mmol/l) over 10 days as measured by CGM versus placebo from baseline to the end of 14 and 26 weeks of dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the effects of cotadutide at different dose levels compared to placebo on body weight</measure>
    <time_frame>26 weeks</time_frame>
    <description>Change and percentage change in body weight versus placebo from baseline to the end of 14 and 26 weeks of dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the effects of cotadutide at different dose levels compared to placebo on body weight</measure>
    <time_frame>26 weeks</time_frame>
    <description>Proportion of participants achieving ≥ 5% and ≥ 10% body weight loss versus placebo from baseline to the end of 14 and 26 weeks of dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the immunogenicity profile of cotadutide compared to placebo</measure>
    <time_frame>30 weeks</time_frame>
    <description>ADAs during the titration treatment period and follow-up period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety and tolerability of cotadutide compared to placebo by assessment of Treatment Emergent Adverse Events (TEAEs) as assessed by CTCAE V4.0</measure>
    <time_frame>26 weeks</time_frame>
    <description>Safety and tolerability of daily SC doses of Cotadutide by assessment of the following using CTCAE V4.0: The number of Treatment Emergent Adverse events (TEAEs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety and tolerability of cotadutide compared to placebo by assessment of Treatment Emergent Serious Adverse Events (TESAEs) as assessed by CTCAE V4.0</measure>
    <time_frame>26 weeks</time_frame>
    <description>Safety and tolerability of daily SC doses of Cotadutide by assessment of the following using CTCAE V4.0: The number of Treatment-Emergent Serious Adverse Events (TESAEs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety and tolerability of cotadutide compared to placebo by assessment of Treatment Emergent Adverse Events of Special Interest (AESIs) as assessed by CTCAE V4.0</measure>
    <time_frame>26 weeks</time_frame>
    <description>Safety and tolerability of daily SC doses of Cotadutide by assessment of the following using CTCAE V4.0: The number of Treatment Emergent Adverse Events of Special Interest (AESIs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety and tolerability of cotadutide compared to placebo by assessment of changes in blood pressure</measure>
    <time_frame>26 weeks</time_frame>
    <description>Number of subjects with clinically significant changes in systolic and diastolic blood pressure (mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety and tolerability of cotadutide compared to placebo by assessment of changes in blood pressure</measure>
    <time_frame>26 weeks</time_frame>
    <description>Percentage of subjects with clinically significant changes in systolic and diastolic blood pressure (mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety and tolerability of cotadutide compared to placebo by assessment of changes in heart rate</measure>
    <time_frame>26 weeks</time_frame>
    <description>Number of subjects with clinically significant changes in heart rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety and tolerability of cotadutide compared to placebo by assessment of changes in heart rate</measure>
    <time_frame>26 weeks</time_frame>
    <description>Percentage of subjects with clinically significant changes in heart rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety and tolerability of cotadutide compared to placebo by assessment of changes in haematology and clinical chemistry parameters</measure>
    <time_frame>26 weeks</time_frame>
    <description>Percentage of subjects with clinically significant changes in in haematology and or clinical chemistry parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety and tolerability of cotadutide compared to placebo by assessment of changes in haematology and clinical chemistry parameters</measure>
    <time_frame>26 weeks</time_frame>
    <description>Number of subjects with clinically significant changes in in haematology and or clinical chemistry parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety and tolerability of cotadutide compared to placebo by assessment of changes in ECG</measure>
    <time_frame>26 weeks</time_frame>
    <description>Number of subjects with an ECG determined to be abnormal and clinically significant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety and tolerability of cotadutide compared to placebo by assessment of changes in ECG</measure>
    <time_frame>26 weeks</time_frame>
    <description>Percentage of subjects with an ECG determined to be abnormal and clinically significant</description>
  </secondary_outcome>
  <other_outcome>
    <measure>To characterise the exposure of cotadutide in participants who have CKD with T2DM</measure>
    <time_frame>26 weeks</time_frame>
    <description>Cotadutide PK exposure (eg, concentrations predose and 4 hours postdose) at steady state. Cotadutide plasma concentrations prior to injection and 4 hours post injection at steady state at different dose levels and different visits over 26 weeks.</description>
  </other_outcome>
  <other_outcome>
    <measure>To assess the effects of cotadutide at different dose levels compared to semaglutide on UACR and compared to placebo and semaglutide on urine albumin and urinary creatinine</measure>
    <time_frame>26 weeks</time_frame>
    <description>Change and percentage change in UACR versus semaglutide from baseline to the end of 14 and 26 weeks dosing&#xD;
Change and percentage change in urine albumin versus placebo and semaglutide from baseline to the end of 14 and 26 weeks dosing&#xD;
Change and percentage change in urinary creatinine versus placebo and semaglutide from baseline to the end of 14 and 26 weeks dosing</description>
  </other_outcome>
  <other_outcome>
    <measure>To assess the effects of cotadutide at different dose levels compared to semaglutide on HbA1c and fasting glucose</measure>
    <time_frame>26 weeks</time_frame>
    <description>Change in HbA1c versus semaglutide from baseline to the end of 14 and 26 weeks dosing&#xD;
Change in fasting glucose versus semaglutide from baseline to the end of 14 and 26 weeks dosing</description>
  </other_outcome>
  <other_outcome>
    <measure>To assess the effects of cotadutide at different dose levels compared to semaglutide on body weight</measure>
    <time_frame>26 weeks</time_frame>
    <description>Change and percentage change in body weight versus semaglutide from baseline to the end of 14 and 26 weeks dosing&#xD;
Proportion of participants achieving ≥ 5% and ≥ 10% body weight loss versus semaglutide from baseline to the end of 14 and 26 weeks dosing</description>
  </other_outcome>
  <other_outcome>
    <measure>To assess the effects of cotadutide at different dose levels compared to placebo and semaglutide on blood pressure</measure>
    <time_frame>26 weeks</time_frame>
    <description>• Change in SBP, DBP versus placebo and/or semaglutide from baseline to the end of 14 and 26 weeks dosing</description>
  </other_outcome>
  <other_outcome>
    <measure>To assess the effects of cotadutide at different dose levels compared to placebo and semaglutide on pulse rate</measure>
    <time_frame>26 weeks</time_frame>
    <description>• Change in pulse rate versus placebo and/or semaglutide from baseline to the end of 14 and 26 weeks dosing</description>
  </other_outcome>
  <other_outcome>
    <measure>To assess the effects of cotadutide at different dose levels compared to placebo and semaglutide on rate pressure product</measure>
    <time_frame>26 weeks</time_frame>
    <description>• Absolute change in rate pressure product versus placebo and/or semaglutide from baseline to the end of 14 and 26 weeks dosing</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">247</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Chronic Kidney Diseases</condition>
  <arm_group>
    <arm_group_label>Cotadutide 100 micrograms</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cotadutide 100 micrograms administered subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cotadutide 300 micrograms</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cotadutide 300 micrograms administered subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cotadutide 600 micrograms</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cotadutide 600 micrograms administered subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Semaglutide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Semaglutide 1.0 miligrams administered subcutaneously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cotadutide 100 micrograms</intervention_name>
    <description>Cotadutide 100 micrograms administered subcutaneously</description>
    <arm_group_label>Cotadutide 100 micrograms</arm_group_label>
    <other_name>MEDI0382</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cotadutide 300 micrograms</intervention_name>
    <description>Cotadutide 300 micrograms administered subcutaneously</description>
    <arm_group_label>Cotadutide 300 micrograms</arm_group_label>
    <other_name>MEDI0382</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cotadutide 600 micrograms</intervention_name>
    <description>Cotadutide 600 micrograms administered subcutaneously</description>
    <arm_group_label>Cotadutide 600 micrograms</arm_group_label>
    <other_name>MEDI0382</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Semaglutide</intervention_name>
    <description>Semaglutide 1.0 miligrams administered subcutaneously</description>
    <arm_group_label>Semaglutide</arm_group_label>
    <other_name>Ozempic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered subcutaneously</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Estimated glomerular filtration rate ≥ 20 to &lt; 90 mL/min/1.73 m2 determined at the&#xD;
             screening visit or a documented occurrence in medical history at least 3 months prior&#xD;
             to randomisation.&#xD;
&#xD;
          -  Receiving background standard of care treatment for renal disease and/or T2DM and&#xD;
             being treated according to locally recognised guidelines, as appropriate.&#xD;
&#xD;
          -  Receiving optimised and stable treatment with an angiotensin-converting-enzyme (ACE)&#xD;
             inhibitor or an angiotensin II receptor antagonist for ≥ 3 months at screening at the&#xD;
             maximum tolerated dose (MTD) unless contraindicated, not tolerated, or in the opinion&#xD;
             of the investigator, not practically available or suitable.&#xD;
&#xD;
          -  Micro- or macroalbuminuria as defined by UACR &gt; 50 mg/g or 5.7 mg/mmol.&#xD;
&#xD;
          -  Diagnosed with T2DM with glucose control managed with any insulin and/or any oral&#xD;
             therapy combination including metformin, SGLT2 inhibitor, thiazolidinedione, or&#xD;
             acarbose where no major dose changes (eg, &gt; 50% increase in dose) have occurred within&#xD;
             the 4 weeks prior to the start of the run-in period. Participants taking sulfonylureas&#xD;
             or glitinides may be randomised following a 4-week washout period of the&#xD;
             sulfonylurea/glitinide.&#xD;
&#xD;
          -  Haemoglobin A1c range of 6.5 % to 12.5% (inclusive) at screening&#xD;
&#xD;
          -  Body mass index &gt; 25 kg/m2 at screening or &gt; 23 kg/m2 for participants enrolled in&#xD;
             Japan&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or presence of significant medical or psychological conditions, including&#xD;
             significant abnormalities in laboratory parameters or vital signs including ECG, which&#xD;
             in the opinion of the investigator, would compromise the participant's safety or&#xD;
             successful participation in the study.&#xD;
&#xD;
          -  Receiving renal replacement therapy or expected to require it within 6 months of being&#xD;
             randomised&#xD;
&#xD;
          -  Renal transplant or on the waiting list for renal transplantation&#xD;
&#xD;
          -  Received a GLP-1 analogue-containing preparation within the last 30 days or 5&#xD;
             half-lives of the drug, if known (whichever is longer), at the time of Visit 2&#xD;
&#xD;
          -  Received any of the following medications within the specified time frame prior to the&#xD;
             start of the study (Visit 2):&#xD;
&#xD;
               1. Aspirin (acetylsalicylic acid) at a dose greater than 150 mg once daily and&#xD;
                  within the last 3 days prior to the start of the run-in period (Visit 2)&#xD;
&#xD;
               2. Paracetamol (acetaminophen) or paracetamol-containing preparations at a total&#xD;
                  daily dose of greater than 3000 mg and within the last 3 days prior to the start&#xD;
                  of the run-in period (Visit 2)&#xD;
&#xD;
               3. Ascorbic acid (vitamin C) supplements at a total daily dose of greater than 1000&#xD;
                  mg and within the last 3 days prior to the start of the run-in period (Visit 2)&#xD;
&#xD;
          -  Participation in another clinical study with an investigational product administered&#xD;
             in the last 30 days or 5 half-lives of the drug, if known (whichever is longer)&#xD;
&#xD;
          -  Participants with a known severe allergy/hypersensitivity to any of the proposed study&#xD;
             interventions or excipients of the product&#xD;
&#xD;
          -  Symptoms of acutely decompensated blood glucose control (eg, thirst, polyuria, weight&#xD;
             loss) or recent episodes of severe hypoglycaemia&#xD;
&#xD;
          -  Type 1 diabetes mellitus (T1DM), history of diabetic ketoacidosis, or clinical&#xD;
             suspicion of T1DM&#xD;
&#xD;
          -  Participants with recent acute or subacute renal function deterioration&#xD;
&#xD;
          -  Significant inflammatory bowel disease, gastroparesis, or other severe disease or&#xD;
             surgery affecting the upper gastrointestinal tract (including weight-reducing surgery&#xD;
             and procedures) which may affect gastric emptying or could affect the interpretation&#xD;
             of safety and tolerability data&#xD;
&#xD;
          -  History of acute or chronic pancreatitis&#xD;
&#xD;
          -  Significant hepatic disease (except for non-alcoholic steatohepatitis or nonalcoholic&#xD;
             fatty liver disease without portal hypertension or cirrhosis) and/or participants with&#xD;
             any of the following results:&#xD;
&#xD;
               1. Aspartate transaminase (AST) ≥ 3 × upper limit of normal (ULN)&#xD;
&#xD;
               2. Alanine transaminase (ALT) ≥ 3 × ULN&#xD;
&#xD;
               3. Total bilirubin ≥ 2 × ULN&#xD;
&#xD;
          -  Poorly controlled hypertension defined as:&#xD;
&#xD;
               1. Systolic BP &gt; 180 mm Hg&#xD;
&#xD;
               2. Diastolic BP ≥ 90 mm Hg after 10 minutes of seated rest and confirmed by repeated&#xD;
                  measurement at screening. Participants who fail BP screening criteria may be&#xD;
                  considered for 24-hour ambulatory BP monitoring at the discretion of the&#xD;
                  investigator. Participants who maintain a mean 24-hour systolic BP ≤ 180 or&#xD;
                  diastolic BP &lt; 90 mm Hg with a preserved nocturnal dip of &gt; 15% will be&#xD;
                  considered eligible&#xD;
&#xD;
          -  Unstable angina pectoris, myocardial infarction, transient ischemic attack or stroke&#xD;
             within 3 months prior to screening, or participants who have undergone percutaneous&#xD;
             coronary intervention or a coronary artery bypass graft within the past 6 months or&#xD;
             who are due to undergo these procedures at the time of screening&#xD;
&#xD;
          -  Decompensated heart failure or hospitalisation for heart failure in the 3 months prior&#xD;
             to screening or symptoms consistent with New York Heart Association heart failure&#xD;
             Class III/IV&#xD;
&#xD;
          -  Basal calcitonin level &gt; 50 ng/L at screening or history/family history of medullary&#xD;
             thyroid carcinoma or multiple endocrine neoplasia&#xD;
&#xD;
          -  History of neoplastic disease within 5 years prior to screening, except for adequately&#xD;
             treated basal cell skin cancer, squamous cell skin cancer, or in situ cervical cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Box Hill</city>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Elizabeth Vale</city>
        <zip>5112</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fitzroy</city>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Melbourne</city>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Merewether</city>
        <zip>2291</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oaklands Park</city>
        <zip>5046</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wollongong</city>
        <zip>2500</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Woolloongabba</city>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Y 3W2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4N 7L3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6S 0C6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Concord</city>
        <state>Ontario</state>
        <zip>L4K 4M2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Etobicoke</city>
        <state>Ontario</state>
        <zip>M9R 4E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6M 1M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K2J 0V2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4G 3E8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 3Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Laval</city>
        <state>Quebec</state>
        <zip>H7T 2P5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 2C6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>10409</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>10437</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dortmund</city>
        <zip>44137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dusseldorf</city>
        <zip>40210</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Essen</city>
        <zip>45359</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ludwigshafen</city>
        <zip>67059</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mainz</city>
        <zip>55116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>München</city>
        <zip>81241</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Münster</city>
        <zip>48145</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Münster</city>
        <zip>48153</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Arakawa-ku</city>
        <zip>116-0012</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chitose-shi</city>
        <zip>066-0032</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fujisawa-shi</city>
        <zip>251-0041</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kamakura-shi</city>
        <zip>247-8533</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Obihiro-shi</city>
        <zip>080-0848</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sapporo-shi</city>
        <zip>060-0062</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shinjyuku-ku</city>
        <zip>160-0022</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Auckland</city>
        <zip>2025</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Auckland</city>
        <zip>?0620</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Christchurch</city>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Grafton</city>
        <zip>1010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Havelock North</city>
        <zip>4130</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tauranga</city>
        <zip>3110</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wellington</city>
        <zip>6021</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Białystok</city>
        <zip>15-435</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krakow</city>
        <zip>30-033</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krakow</city>
        <zip>31-261</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lublin</city>
        <zip>20064</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <zip>40-081</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poznań</city>
        <zip>61-655</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-507</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>La Coruna</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lérida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Majadahonda</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Palma de Mallorca</city>
        <zip>07010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pozuelo de Alarcón</city>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Japan</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 6, 2020</study_first_submitted>
  <study_first_submitted_qc>August 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2020</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MEDI0382</keyword>
  <keyword>T2DM</keyword>
  <keyword>Cotadutide</keyword>
  <keyword>Diabetic Kidney Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.&#xD;
Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_time_frame>
    <ipd_access_criteria>When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_access_criteria>
    <ipd_url>https://astrazenecagroup-dt.pharmacm.com/DT/Home</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

